NCT02829918 2026-03-11
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
261 trialsNCT03370276 2026-03-10
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT04396860 2026-03-05
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT03358719 2026-02-27
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT03400332 2026-02-24
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04526730 2026-02-20
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02523469 2026-02-17
ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Medical University of South Carolina
Phase 1/2 Completed
NCT03143153 2026-02-17
CheckMate 648
Bristol-Myers Squibb
Phase 3 Completed
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT03785873 2026-02-13
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT04552223 2026-02-11
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
University of Miami
Phase 2 Completed
NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
NCT03829722 2026-01-22
Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03285321 2026-01-20
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT03575793 2026-01-20
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 1/2 Completed
NCT03994601 2026-01-20
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03267498 2026-01-12
Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)
University of California, San Francisco
Phase 2 Completed
NCT04326257 2026-01-08
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
Phase 2 Completed
NCT01968109 2026-01-06
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT03172624 2025-12-18
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03388632 2025-12-18
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03215706 2025-12-17
CheckMate 9LA
Bristol-Myers Squibb
Phase 3 Completed
NCT04349267 2025-12-17
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03377361 2025-12-03
CheckMate 9N9
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04021043 2025-12-03
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02743494 2025-11-18
CheckMate 577
Bristol-Myers Squibb
Phase 3 Completed
NCT03369223 2025-11-18
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02939300 2025-11-14
Ipilimumab and Nivolumab in Leptomeningeal Metastases
Massachusetts General Hospital
Phase 2 Completed
NCT03021993 2025-11-12
Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
Medical University of South Carolina
Phase 2 Completed
NCT02823990 2025-11-10
TG4010 and Nivolumab in Patients With Lung Cancer
University of California, Davis
Phase 2 Completed
NCT02060188 2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2 Completed
NCT03557359 2025-11-03
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Columbia University
Phase 2 Completed
NCT02477826 2025-10-30
CheckMate 227
Bristol-Myers Squibb
Phase 3 Completed
NCT04208958 2025-10-27
ConsortiumIO
Vedanta Biosciences, Inc.
Phase 1/2 Completed
NCT01592370 2025-10-22
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03906071 2025-10-21
SAPPHIRE
Mirati Therapeutics Inc.
Phase 3 Completed
NCT03573947 2025-10-14
TOP1705
Duke University
Phase 2 Completed
NCT03404960 2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2 Completed
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03963518 2025-10-06
SURROGATE-ICI
Institut Bergonié
Completed
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03711058 2025-09-16
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT03195478 2025-09-15
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02498600 2025-08-29
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02327078 2025-08-14
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03636477 2025-08-12
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
Alaunos Therapeutics
Phase 1 Completed